117,679 Shares in Teladoc Health, Inc. $TDOC Bought by Havemeyer Place LP

Havemeyer Place LP purchased a new position in shares of Teladoc Health, Inc. (NYSE:TDOCFree Report) during the fourth quarter, Holdings Channel.com reports. The fund purchased 117,679 shares of the health services provider’s stock, valued at approximately $824,000.

Other hedge funds have also recently added to or reduced their stakes in the company. IFP Advisors Inc boosted its holdings in Teladoc Health by 412.1% during the third quarter. IFP Advisors Inc now owns 3,989 shares of the health services provider’s stock worth $31,000 after buying an additional 3,210 shares in the last quarter. PNC Financial Services Group Inc. boosted its holdings in Teladoc Health by 177.7% during the fourth quarter. PNC Financial Services Group Inc. now owns 4,391 shares of the health services provider’s stock worth $31,000 after buying an additional 2,810 shares in the last quarter. Aster Capital Management DIFC Ltd boosted its holdings in Teladoc Health by 101.1% during the third quarter. Aster Capital Management DIFC Ltd now owns 4,823 shares of the health services provider’s stock worth $37,000 after buying an additional 2,425 shares in the last quarter. International Assets Investment Management LLC purchased a new stake in Teladoc Health during the fourth quarter worth $45,000. Finally, KBC Group NV boosted its holdings in Teladoc Health by 88.3% during the fourth quarter. KBC Group NV now owns 9,632 shares of the health services provider’s stock worth $67,000 after buying an additional 4,516 shares in the last quarter. 76.82% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Teladoc Health

In other Teladoc Health news, insider Fernando M. Rodrigues sold 5,677 shares of the company’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total value of $43,315.51. Following the completion of the sale, the insider directly owned 9,572 shares in the company, valued at $73,034.36. This represents a 37.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Adam C. Vandervoort sold 7,906 shares of the firm’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total value of $60,322.78. Following the completion of the sale, the insider directly owned 110,261 shares of the company’s stock, valued at $841,291.43. This trade represents a 6.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 67,601 shares of company stock valued at $454,750 over the last ninety days. 0.70% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the stock. Stifel Nicolaus lowered their price target on shares of Teladoc Health from $8.00 to $6.00 and set a “hold” rating on the stock in a report on Thursday, February 26th. Oppenheimer lowered their price target on shares of Teladoc Health from $12.00 to $7.00 and set an “outperform” rating on the stock in a report on Tuesday, March 3rd. Piper Sandler reissued an “overweight” rating and set a $9.00 price target (down from $12.00) on shares of Teladoc Health in a report on Thursday, February 26th. TD Cowen decreased their price objective on shares of Teladoc Health from $8.00 to $6.00 and set a “hold” rating on the stock in a report on Thursday, February 26th. Finally, Leerink Partners decreased their price objective on shares of Teladoc Health from $8.50 to $5.50 and set a “market perform” rating on the stock in a report on Thursday, February 26th. Five analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $7.43.

View Our Latest Stock Analysis on TDOC

Teladoc Health Price Performance

Shares of NYSE TDOC opened at $7.07 on Tuesday. The firm has a 50-day simple moving average of $6.23 and a 200-day simple moving average of $6.22. The stock has a market capitalization of $1.28 billion, a price-to-earnings ratio of -7.28 and a beta of 2.14. The company has a quick ratio of 2.72, a current ratio of 2.80 and a debt-to-equity ratio of 0.75. Teladoc Health, Inc. has a 52 week low of $4.40 and a 52 week high of $9.77.

Teladoc Health (NYSE:TDOCGet Free Report) last issued its earnings results on Wednesday, April 29th. The health services provider reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.01). The business had revenue of $613.85 million during the quarter, compared to analyst estimates of $611.04 million. Teladoc Health had a negative net margin of 6.81% and a negative return on equity of 11.45%. Teladoc Health’s quarterly revenue was down 2.5% on a year-over-year basis. During the same quarter last year, the company earned ($0.53) earnings per share. Teladoc Health has set its FY 2026 guidance at -1.050–0.750 EPS and its Q2 2026 guidance at -0.300–0.200 EPS. On average, equities analysts predict that Teladoc Health, Inc. will post -0.92 earnings per share for the current fiscal year.

Teladoc Health Profile

(Free Report)

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.

Further Reading

Want to see what other hedge funds are holding TDOC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teladoc Health, Inc. (NYSE:TDOCFree Report).

Institutional Ownership by Quarter for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.